Kim Vanstraelen1, Anca Colita, Ana Maria Bica, Raf Mols, Patrick Augustijns, Nele Peersman, Pieter Vermeersch, Pieter Annaert, Isabel Spriet. 1. From the *Clinical Pharmacology and Pharmacotherapy, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, University Hospitals Leuven, Leuven, Belgium; †Pediatric Department, Fundeni Clinical Institute; ‡Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; §Drug Delivery and Disposition, KU Leuven Department of Pharmaceutical and Pharmacological Sciences; and ¶Clinical Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
Abstract
BACKGROUND: Antifungal prophylaxis remains challenging in immunocompromised children as no clear consensus has yet been reached about which drug to be used. Posaconazole has a broad spectrum of activity, a favorable safety profile and excellent prophylactic activity in adults. However, a lack of pharmacokinetic studies in pediatric patients hampers routine implementation. This study investigates the pharmacokinetics of a newly introduced posaconazole dosing regimen based on the body surface area in pediatric hematologic patients. METHODS: In this prospective pharmacokinetic study, 8 blood samples were taken during 1 dosing interval at steady state in children aged 13 years or younger with hematologic malignancy, who were treated prophylactically with posaconazole oral suspension at a dose of 120 mg/m 3 times daily. Posaconazole plasma concentrations were determined using high-performance liquid chromatography fluorescence detection. RESULTS: One hundred twelve samples were taken from 14 patients with a mean age of 6.7 ± 2.8 years. A median posaconazole daily dose of 100.0 mg (77.3-100.0) 3 times daily (tid), corresponding to a median of 117.9 mg/m (112.2-120.4) tid, resulted in mean trough posaconazole plasma concentrations of 0.85 ± 0.56 mg/L. Pharmacokinetic analysis revealed a clearance of 0.8 L/(h kg) (0.5-1.4). No invasive fungal infections or adverse events were encountered during treatment. CONCLUSIONS: Posaconazole is a promising antifungal agent to be used prophylactically in hematologic patients aged 13 years or younger. Administering posaconazole oral suspension in a dosage of 120 mg/m tid results in adequate posaconazole plasma exposure, without significant adverse events.
BACKGROUND: Antifungal prophylaxis remains challenging in immunocompromised children as no clear consensus has yet been reached about which drug to be used. Posaconazole has a broad spectrum of activity, a favorable safety profile and excellent prophylactic activity in adults. However, a lack of pharmacokinetic studies in pediatric patients hampers routine implementation. This study investigates the pharmacokinetics of a newly introduced posaconazole dosing regimen based on the body surface area in pediatric hematologic patients. METHODS: In this prospective pharmacokinetic study, 8 blood samples were taken during 1 dosing interval at steady state in children aged 13 years or younger with hematologic malignancy, who were treated prophylactically with posaconazole oral suspension at a dose of 120 mg/m 3 times daily. Posaconazole plasma concentrations were determined using high-performance liquid chromatography fluorescence detection. RESULTS: One hundred twelve samples were taken from 14 patients with a mean age of 6.7 ± 2.8 years. A median posaconazole daily dose of 100.0 mg (77.3-100.0) 3 times daily (tid), corresponding to a median of 117.9 mg/m (112.2-120.4) tid, resulted in mean trough posaconazole plasma concentrations of 0.85 ± 0.56 mg/L. Pharmacokinetic analysis revealed a clearance of 0.8 L/(h kg) (0.5-1.4). No invasive fungal infections or adverse events were encountered during treatment. CONCLUSIONS:Posaconazole is a promising antifungal agent to be used prophylactically in hematologic patients aged 13 years or younger. Administering posaconazole oral suspension in a dosage of 120 mg/m tid results in adequate posaconazole plasma exposure, without significant adverse events.
Authors: T Jancel; P A Shaw; C W Hallahan; T Kim; A F Freeman; S M Holland; S R Penzak Journal: J Clin Pharm Ther Date: 2016-12-16 Impact factor: 2.512
Authors: Antonio C Arrieta; Lillian Sung; John S Bradley; C Michel Zwaan; Davis Gates; Hetty Waskin; Patricia Carmelitano; Andreas H Groll; Thomas Lehrnbecher; Eric Mangin; Amita Joshi; Nicholas A Kartsonis; Thomas J Walsh; Amanda Paschke Journal: PLoS One Date: 2019-03-26 Impact factor: 3.240
Authors: Sophida Boonsathorn; Iek Cheng; Frank Kloprogge; Carlos Alonso; Charmion Lee; Bilyana Doncheva; John Booth; Robert Chiesa; Adam Irwin; Joseph F Standing Journal: Clin Pharmacokinet Date: 2019-01 Impact factor: 6.447
Authors: Arathi A Lambrix; Hope D Swanson; Jennifer L Pauley; Allison W Bragg; Delia C Carias; Melissa S Bourque; Yinmei Zhou; Cheng Cheng; William L Greene; Gabriela Maron Journal: J Antimicrob Chemother Date: 2020-12-01 Impact factor: 5.790